ArticleThe Journal of experimental medicine2017
IL-22BP dictates characteristics of Peyer's patch follicle-associated epithelium for antigen uptake.
Article in The Journal of experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 60 citations in OpenAlex.
- Control of Intestinal Type 3 Immunity by the Unfolded Protein Response Sensor Inositol-Requiring Enzyme 1α in Antigen-Presenting Cells.Cellular and molecular gastroenterology and hepatology · 2026Article
- Peyer's patch M cells organize an epithelial niche that sustains group 3 innate lymphoid cells and IL-22.Nature immunology · 2026Article
- Contribution of Interleukin-22 Binding Protein to the Development of Allergen-Induced Airway Hyperresponsiveness.International journal of molecular sciences · 2026Article
- Pyruvate-GPR31 axis induces LysoDC dendrite protrusion to M-cell pockets for effective immune responses.Gut microbes · 2025Article
- Antigen-presenting cells as arbiters of mucosal tolerance and immunity.Nature immunology · 2025Review
- Wild-type bone marrow cells repopulate tissue resident macrophages and reverse the impacts of homozygous CSF1R mutation.PLoS genetics · 2025Article
- Deficiency of IL-22-binding protein enhances the ability of the gut microbiota to protect against enteric pathogens.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Discrimination of distinct chicken M cell subsets based on CSF1R expression.Scientific reports · 2024Article
- Role of the type 3 cytokines IL-17 and IL-22 in modulating metabolic dysfunction-associated steatotic liver disease.Frontiers in immunology · 2024Review
- C5aRNPJ vaccines · 2023Article
- Gut-liver axis: barriers and functional circuits.Nature reviews. Gastroenterology & hepatology · 2023Review
- Effects of Royal Jelly on Gut Dysbiosis and NAFLD inNutrients · 2023Article
- CD4 T-Cell Subsets and the Pathophysiology of Inflammatory Bowel Disease.International journal of molecular sciences · 2023Review
- The intestinal microenvironment shapes macrophage and dendritic cell identity and function.Immunology letters · 2023Review
- IL-22BP production is heterogeneously distributed in Crohn's disease.Frontiers in immunology · 2022Article
- Dendritic cell functions in the inductive and effector sites of intestinal immunity.Mucosal immunology · 2022Review
- From digestion and absorption to innate immunity and health care: water and food intake may contribute to IL-22 in ILC3-dependent mucosal immunity in the jejunum.The journal of physiological sciences : JPS · 2021Review
- IL-22 receptor signaling in Paneth cells is critical for their maturation, microbiota colonization, Th17-related immune responses, and anti-Salmonella immunity.Mucosal immunology · 2021Article
- IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology.Frontiers in immunology · 2021Review
- Recent Insights into Cellular Crosstalk in Respiratory and Gastrointestinal Mucosal Immune Systems.Immune network · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-22 (IL-22) acts protectively and harmfully on intestinal tissue depending on the situation; therefore, IL-22 signaling needs to be tightly regulated. IL-22 binding protein (IL-22BP) binds IL-22 to inhibit IL-22 signaling. It is expressed in intestinal and lymphoid tissues, although its precise distribution and roles have remained unclear. In this study, we show that IL-22BP is highly expressed by CD11b
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.